ICE 1207
Alternative Names: ICE-1207Latest Information Update: 04 Aug 2021
At a glance
- Originator iCeutica
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 28 Jul 2021 ICE 1207 is available for licensing as of 28 Jul 2021. http://www.iceutica.com/products/products.php#page-pipeline
- 28 Jul 2021 Preclinical trials in Lung cancer in USA (PO), prior to July 2021 (iCeutica pipeline, July 2021)